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Abstract 
 Cancer is a cause of death worldwide and the socio-economic impact 
of cancer is enormous and disturbing. Breast cancer is becoming a significant 
health concern for women across Nigeria and immune instability may be 
responsible. Therefore, the present study was designed to assess the immune 
stability of breast cancer subjects using CD4 + T cell, CD8 + T cell counts 
and the CD4/CD8 ratio. One hundred subjects were randomly recruited for 
the study and grouped into Breast cancer subjects (BCA) (n=50) and control 
(n=50). CD4 + T cells (µl/count) and CD8 + T cells (µl/count) were 
estimated using flow cytometric method while CD4/CD8 ratio was 
calculated from the values obtained from the CD4 + T cells and CD8 + T 
cells. CD4+ T cells and CD8+ T cells showed significant decrease (p<0.05) 
in the breast cancer subjects compared to the control subjects. The 
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suppressed CD4 + and CD8 + T cell counts in breast cancer subjects may 
indicate immune instability in the cancer subjects. 
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Introduction 
 Cancer has become an increasingly important public health problem 
in developing countries, including Africa (Farmer et al, 2010). As public and 
professional awareness of the cancer problem has grown, so has interest in 
the pattern of disease diagnosis and treatment outcome. Breast cancer is the 
most frequently diagnosed malignancy and the second principal cause of 
death among women worldwide as well as in Nigeria (Okobia et al, 2006). It 
is the leading cause of cancer death among females accounting for 23% (1.38 
million) of the total cancer cases and 14% (458,400) of the cancer deaths in 
women (Jemal et al, 2011). 
 It has also been shown that the development of cancer is associated 
with alterations in numbers and functions of immune cells in the peripheral 
circulation and especially at the sites of tumor progression (Whitefield, 
2013). Antigen-specific immune responses result from a complex dynamic 
interplay between antigen presenting cells, T lymphocytes, and target cells 
(Scott et al, 2012). The mechanisms of tumor cell killing by antibodies can 
be due to direct cell killing, such as through receptor blockade or agonist 
activity, induction of apoptosis, or delivery of a drug, radiation, or cytotoxic 
agent; immune-mediated cell killing mechanisms; regulation of T cell 
function; and specific effects on tumor vasculature and stroma. McArdle et 
al (2004) stated that disease progression in cancer is not solely determined 
by the characteristics of the tumour but also by the host response). Liu et al 
(2012) reported that immune response may play an important role in cancer 
progression. Tumor-infiltrating lymphocytes (TILs) reflect a local immune 
response and could be a key mechanism in controlling tumor progression 
(Mahmoud et al, 2011, Mahmoud et al, 2012). Tumor-derived factors have 
been shown to induce death of immune cells at the tumor sites and in the 
peripheral circulation (Whiteside, 2010). The frequency of CD8+ T cells 
undergoing spontaneous apoptosis in the blood of patients with cancer was 
found to be significantly elevated relative to that in sex- or age-matched 
healthy controls (Hoffmann et al., 2002). CD8+ T cells were preferentially 
targeted for cell death compared to circulating CD4+ T cells (Tsukishiro, 
2003). Therefore, the study aimed to assess the immune stability of breast 
cancer subjects using CD4 + T cells, CD8 + T cell counts and the CD4/CD8 
ratio.  
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Methods 
 Breast cancer subjects who were attending the general Surgery 
Department (Surgical Out Patients’ Clinic) of the Nnamdi Azikiwe 
University Teaching Hospital (NAUTH) were investigated. Ethical clearance 
was obtained from the Ethics Committee of the Nnamdi Azikiwe University 
Teaching Hospital (NAUTH). A total of fifty breast cancer subjects were 
recruited using non probability consecutive sampling. The mean age of the 
breast cancer subjects was 43 ± 12 years. Twenty seven subjects were in 
stage 0, eighteen in stage 1 and five subjects were in stage 3 at the time they 
were recruited. A total number of twenty three subjects were on 
chemotherapy and they received four courses of combination therapy of 
Cyclophosphamide, (500mg/m2), Adriamycin (50mg/m2) and 5-Fluorouracil 
(500mg/m2). The drugs were given at intervals of three weeks. 
 A total of fifty apparently healthy females without any family history 
of cancer participated in the study. The mean age of the subjects was 40±10 
years. They were recruited after they underwent self and clinical breast 
examination and no clinical tumour was observed. The subjects were 
apparently healthy subjects without any other diseased condition. 
 Two milliliters of blood samples were collected from each subjects 
into Disodium ethylenediaminetetraaceticacid (EDTA) for the estimation of 
CD4 + and CD8 + T cells within 2 hours of collection using flow cytometric 
method (Fryland, 2006).  
 The Mean and Standard Deviation (SD) were calculated for each 
parameter. Differences in the means for each parameter between the two 
groups were compared using Student’s t test and analysis of variance 
(ANOVA). 
 
Results 
 The results are presented in tables. The results show that CD4 + T 
cells and CD8 + T cells in the breast cancer subjects were significantly 
decreased (p<0.05) compare with the control subjects while the CD4/CD8 
ratio show significant increase (Table 1). There was no significance 
difference in CD4 + T cells, CD8 + T cells and CD4/CD8 ratio based on 
stages and chemotherapy (Table 2 and 3). 
Table 1 : Immune status in breast cancer subjects 
Parameters Breast cancer Control P value 
CD4+ T cells (µl/count) 675± 100 1045± 322 0.000* 
CD8 +T cells (µl/count) 364± 50 775 ±100 0.000* 
CD4/CD8 Ratio 1.87 ±0.24 1.65 ±0.29 0000* 
*significant at p<0.05 
Table 2: Immune status in breast cancer according to stages 
Parameters 
Breast cancer 
subjects in 
stage 0 
n=27 
Breast cancer subjects in 
stage 1 
n=18 
Breast cancer subjects in 
stage 3 
n=5 
F-
values 
P-
values 
CD4+ T cells 693 ± 96 663 ± 102 624 ± 112 1.229 0.302 
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(µl/count) 
CD8 +T cells 
(µl/count) 371± 55 362 ± 44 337 ± 41 0.970 0.386 
CD4/CD8 Ratio 1.89 ± 0.27 1.83 ± 0.17 1.86 ± 0.32 0.292 0.748 
Table 3: Immune status in breast cancer subjects based on chemotherapy 
Parameters 
Breast cancer subjects not on 
chemotherapy 
N=27 
Breast cancer subjects on 
chemotherapy 
N=23 
P-
values 
CD4+ T cells 
(µl/count) 680 ±  93 670 ±   108 0.737 
CD8 +T cells 
(µl/count) 362  ±   40 368 ± 61 0.691 
CD4/CD8 Ratio 1.89 ± 0 .24 1.84± 0 .24 0.519 
 
Discussion 
 The study observed significant decrease in the levels of CD4 + and 
CD8 + T cells in breast cancer subjects. Other studies have associated this 
finding with the spread of disease in patients with breast, malignant 
melanoma, lung, and colorectal cancers (Blake-Mortimer et al, 2004). The 
frequency of CD8+ T cells undergoing spontaneous apoptosis in the blood of 
patients with cancer was found to be significantly elevated relative to sex- or 
age-matched healthy controls (Hoffmann et al., 2002). This is because CD8+ 
T cells were preferentially targeted for cell death compared to circulating 
CD4+ T cells (Tsukishiro et al., 2003). Blake-Mortimer et al (2004) had 
related higher cytotoxic T lymphocytes (CTL) count to longer survival and 
that CTL count was significantly associated with other subsets, such as 
helper T cells which also play a crucial role in cell-mediated immunity. Liu 
et al (2012) has shown that tumor-infiltrating lymphocytes (TILs) in the 
tumor microenvironment are predominantly CD8+ T cells and they produce 
interferon-gamma through interaction with tumor-related antigens, 
potentially leading to tumoricidal activity by induction of apoptosis and / or 
macrophage tumor killing activity. The implication of the significant 
decrease of CD8+ T cells in breast cancer subject is that it may lead to 
reduced survival in breast cancer subjects since the CD8+ T cells were 
preferentially targeted for cell death compared to circulating CD4+ T cells 
according to Tsukishiro et al (2003) and Blake-Mortimer et al (2004). 
 It was concluded that there was immune instability in the breast 
cancer subjects compared with the control subjects. 
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